Drugs / Abicipar pegol
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03335852 | Nov 2017 → Oct 2018 | macular degeneration | Allergan | Completed | No outcome recorded |
| Phase 1 | NCT02859766 | Dec 2016 → Oct 2017 | macular degeneration | Allergan | Completed | No outcome recorded |
| Phase 1 | NCT01086761 | Mar → Nov 2010 | wet macular degeneration | Allergan | Terminated | No outcome recorded |
| Phase 1 | NCT01042678 | Feb → Dec 2010 | diabetic macular edema | Allergan | Terminated | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03539549 | May 2018 → Feb 2019 | macular degeneration | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT02181504 | Sep 2014 → Dec 2015 | macular degeneration | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT02181517 | Jul 2014 → Mar 2015 | age-related macular degeneration | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT02186119 | Jul 2014 → Jun 2015 | macular retinal edema | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01397409 | Sep 2011 → Mar 2014 | age-related macular degeneration | Allergan | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02462928 | Jun 2015 → Apr 2018 | macular degeneration | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT02462486 | Jun 2015 → Apr 2018 | macular degeneration | Allergan | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-06-26 | AbbVie | Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol abbvie.com ↗ |
| 2019-10-11 | AbbVie | Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration abbvie.com ↗ |
| 2019-09-09 | AbbVie | Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration abbvie.com ↗ |
| 2019-04-02 | AbbVie | Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol abbvie.com ↗ |
| 2018-07-19 | AbbVie | Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration abbvie.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abicipar Pegol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02462928 ↗ |
| Known as | AGN-150998 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01397409 ↗ |
| Known as | MP-0260 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297684 ↗ |
| Known as | MP0112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01042678 ↗ |
| Known as | P7FHD7AG35 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297684 ↗ |
| Known as | Vegf-a binding darpin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297684 ↗ |
| Action | Inhibit | “a novel, potentially long acting VEGF inhibitor” NCT01042678 ↗ |
| Modality | Protein / enzyme biologic | “MP0112, a designed ankyrin repeat protein (DARPin)” PMID 24907435 ↗ Jun 2014 |
| Route | Intravitreal | “Single intravitreal injection of MP0112 in the study eye” NCT01042678 ↗ |
| Target | VEGFA | “MP0112, a designed ankyrin repeat protein (DARPin) that binds with high affinity to vascular endothelial growth factor-A (VEGF-A)” PMID 24907435 ↗ Jun 2014 |